234 related articles for article (PubMed ID: 27734608)
1. Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models.
Zopf D; Fichtner I; Bhargava A; Steinke W; Thierauch KH; Diefenbach K; Wilhelm S; Hafner FT; Gerisch M
Cancer Med; 2016 Nov; 5(11):3176-3185. PubMed ID: 27734608
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
Huynh H; Ong R; Zopf D
J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of regorafenib and lapatinib in preclinical models of human colorectal cancer.
Zhang WJ; Li Y; Wei MN; Chen Y; Qiu JG; Jiang QW; Yang Y; Zheng DW; Qin WM; Huang JR; Wang K; Zhang WJ; Wang YJ; Yang DH; Chen ZS; Shi Z
Cancer Lett; 2017 Feb; 386():100-109. PubMed ID: 27864115
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in metastatic colorectal cancer.
Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
[TBL] [Abstract][Full Text] [Related]
8. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real-world treatment outcomes.
Fukudo M; Asai K; Tani C; Miyamoto M; Ando K; Ueno N
Invest New Drugs; 2021 Oct; 39(5):1422-1431. PubMed ID: 33830408
[TBL] [Abstract][Full Text] [Related]
12. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Mross K; Frost A; Steinbild S; Hedbom S; Büchert M; Fasol U; Unger C; Krätzschmar J; Heinig R; Boix O; Christensen O
Clin Cancer Res; 2012 May; 18(9):2658-67. PubMed ID: 22421192
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib for cancer.
Strumberg D; Schultheis B
Expert Opin Investig Drugs; 2012 Jun; 21(6):879-89. PubMed ID: 22577890
[TBL] [Abstract][Full Text] [Related]
16. Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.
Kim J; Ulu A; Wan D; Yang J; Hammock BD; Weiss RH
Mol Cancer Ther; 2016 May; 15(5):890-8. PubMed ID: 26921392
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites.
Fujita KI; Masuo Y; Yamazaki E; Shibutani T; Kubota Y; Nakamichi N; Sasaki Y; Kato Y
J Pharm Sci; 2017 Sep; 106(9):2632-2641. PubMed ID: 28479358
[TBL] [Abstract][Full Text] [Related]
18. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib in the treatment of colorectal cancer.
Majithia N; Grothey A
Expert Opin Pharmacother; 2016; 17(1):137-45. PubMed ID: 26559195
[TBL] [Abstract][Full Text] [Related]
20. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]